Gregory J Nason1, Khaled Ajib1, Guan Hee Tan1, Dixon T S Woon1, George T Christakis2, Robert K Nam1. 1. Division of Urology, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada. 2. Division of Cardiac Surgery, Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada.
Abstract
INTRODUCTION: Patients with renal cell carcinoma (RCC) with level 3 or 4 caval thrombus have a poor prognosis, with reported five-year survival rates of 30-40%. The aim of this study was to assess the perioperative morbidity and long-term oncological outcomes for radical nephrectomy with resection of vena cava thrombus using a combined surgical approach, including extracorporeal circulation and deep hypothermic circulatory arrest. METHODS: A retrospective review was performed of the institutional case log to identify all radical nephrectomies with caval thrombus performed from January 2006 to May 2020. RESULTS: Twenty-five patients were identified with level 2 thrombus in one (4%), level 3 thrombus in eight (32%), and level 4 in 16 (64%). The median followup was 20.6 months (range 0.2-133.3). The median age at surgery was 68.4 years (range 44.2-85.5). Twenty-one (84%) patients were symptomatic at presentation. Six (24%) patients had distant metastases at diagnosis. The median circulatory arrest time was 15 minutes (range 6-35). The 30-day grade ≥3 complication rate was 8%. The 30-day mortality rate was 8%. The one-year, two-year, three-year, and five-year recurrence-free survival (RFS) rates were 53%, 18%, 10%, and 10%, respectively. The median time to systemic treatment was 7.7 months (range 1.2-25.7). The one-year, two-year, three-year, and five-year overall survival (OS) rates were 70%, 43%, 36%, and 31%, respectively. CONCLUSIONS: Radical nephrectomy with resection of vena cava thrombus using extracorporeal circulation and deep hypothermic circulatory arrest is associated with some morbidity and mortality but remains a safe and effective strategy for advanced RCC patients who would otherwise be managed palliatively.
INTRODUCTION:Patients with renal cell carcinoma (RCC) with level 3 or 4 caval thrombus have a poor prognosis, with reported five-year survival rates of 30-40%. The aim of this study was to assess the perioperative morbidity and long-term oncological outcomes for radical nephrectomy with resection of vena cava thrombus using a combined surgical approach, including extracorporeal circulation and deep hypothermic circulatory arrest. METHODS: A retrospective review was performed of the institutional case log to identify all radical nephrectomies with caval thrombus performed from January 2006 to May 2020. RESULTS: Twenty-five patients were identified with level 2 thrombus in one (4%), level 3 thrombus in eight (32%), and level 4 in 16 (64%). The median followup was 20.6 months (range 0.2-133.3). The median age at surgery was 68.4 years (range 44.2-85.5). Twenty-one (84%) patients were symptomatic at presentation. Six (24%) patients had distant metastases at diagnosis. The median circulatory arrest time was 15 minutes (range 6-35). The 30-day grade ≥3 complication rate was 8%. The 30-day mortality rate was 8%. The one-year, two-year, three-year, and five-year recurrence-free survival (RFS) rates were 53%, 18%, 10%, and 10%, respectively. The median time to systemic treatment was 7.7 months (range 1.2-25.7). The one-year, two-year, three-year, and five-year overall survival (OS) rates were 70%, 43%, 36%, and 31%, respectively. CONCLUSIONS: Radical nephrectomy with resection of vena cava thrombus using extracorporeal circulation and deep hypothermic circulatory arrest is associated with some morbidity and mortality but remains a safe and effective strategy for advanced RCCpatients who would otherwise be managed palliatively.
Authors: Brian Shuch; Paul L Crispen; Bradley C Leibovich; Jeff C LaRochelle; Frederic Pouliot; Allan J Pantuck; Weiqing Liu; Maxime Crepel; Anne Schuckman; Jerome Rigaud; Oliver Bouchot; Jean-Jacques Patard; Donald Skinner; Arie S Belldegrun; Michael L Blute Journal: BJU Int Date: 2011-03 Impact factor: 5.588
Authors: Stanley A Yap; David Horovitz; Shabbir M H Alibhai; Robert Abouassaly; Narhari Timilshina; Antonio Finelli Journal: BJU Int Date: 2012-04-13 Impact factor: 5.588
Authors: Axel Haferkamp; Patrick J Bastian; Hildegard Jakobi; Maria Pritsch; Jesco Pfitzenmaier; Peter Albers; Peter Hallscheidt; Stefan C Müller; Markus Hohenfellner Journal: J Urol Date: 2007-05 Impact factor: 7.450
Authors: Gregory J Nason; Barry B McGuire; Michael E Kelly; Theodore M Murphy; Aisling T Looney; Damien P Byrne; David W Mulvin; David J Galvin; David M Quinlan; Gerald M Lennon Journal: Can Urol Assoc J Date: 2014-03 Impact factor: 1.862